AI platforms for protein and enzyme design bring together specialized generative models (exemplified by DISCO and other next‑generation bio‑design tools), scalable compute, curated training data, and orchestration layers that bridge in silico design with experimental workflows. As of 2026, advances in structure prediction and generative sequence models have shifted the field from single-model experiments to integrated platforms that prioritize reproducibility, data provenance, and governed deployment. Key components include: high-performance training and inference infrastructure (e.g., Together AI) to fine‑tune and deploy large bio‑models at scale; data‑curation services (DatologyAI) that convert raw experimental records into model‑ready datasets with consistent labels and provenance; no‑code/low‑code orchestration and agent platforms (StackAI) to automate multi‑step design-evaluate cycles; and enterprise assistants and multimodal LLMs (IBM watsonx Assistant, Claude family, Google Gemini) that support hypothesis generation, protocol drafting, and regulatory documentation. Research and discovery are further supported by tools such as ChatPDF and Perplexity AI for rapid literature grounding and sourced answers. Together these layers address common bottlenecks: quality of training data, scalable model optimization, reproducible pipelines, and traceable outputs required for downstream lab validation and regulatory review. Marketplaces and research tool integrators are increasingly important for discovering validated models, composable components, and compliance artifacts. Practical adoption now emphasizes transparent validation, interoperable APIs, and governance controls over purely synthetic performance claims. In short, the ecosystem is maturing from proof‑of‑concept models to production‑oriented platforms that couple generative design with the infrastructure and data practices needed for reliable enzyme and protein engineering.